Prior to Deciphera, Dr. Dhanak served as Chief Scientific Officer and Executive Vice President at Incyte
Corporation. Before joining Incyte in 2018, Dr. Dhanak was Vice President and Head of Discovery Sciences at Janssen Research & Development, and previously spent 25 years at GlaxoSmithKline in positions of increasing responsibility
across multiple disease areas, including his final role as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit. Dr. Dhanak received a B.Sc. in Chemistry from the University of Manchester Institute of Science and
Technology and a Ph.D. from the University of London. He completed his postdoctoral research in Natural Product Synthesis at Northwestern University.
In
addition, the Company announced today that Ron Squarer has been appointed Chairperson of the Board of Directors. Mr. Squarer has over 30 years of experience in the pharmaceutical and biotechnology industry and joined Deciphera as a
Director in December 2019. Mr. Squarer served as Chief Executive Officer and a member of the board of directors of Array BioPharma, Inc. from 2012 until its acquisition by Pfizer Inc. in August 2019 following the successful commercial launches
of both Braftovi® and Mektovi®. James A. Bristol, Ph.D., who has served as either Chairperson or
Co-Chairperson since 2007, will remain a Board member of Deciphera.
“I want to recognize Jim Bristol’s
tremendous leadership as Chairperson of the Deciphera board for over 15 years. Jim’s deep industry expertise has been invaluable in guiding our research activities, scaling our organization, and transforming Deciphera into a leading
commercial-stage oncology company. We thank him for his exceptional stewardship as Chairperson and look forward to his continued contributions as a member of the board,” said Mr. Hoerter.
About Deciphera Pharmaceuticals
Deciphera is a
biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in
kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s
switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States.
For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended, including, without limitation, the ability for Deciphera to develop additional important new medicines for the treatment of cancer and to become a company with multiple approved medicines. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
“potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially
from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, our ability to successfully demonstrate the efficacy and safety of our drug or drug candidates,